Dyck G, Maayah Z, Eurich D, Dyck J
Schizophr Bull Open. 2024; 3(1):sgab053.
PMID: 39144756
PMC: 11205871.
DOI: 10.1093/schizbullopen/sgab053.
Crown L, Agyeman K, Choi W, Zepeda N, Iseri E, Pahlavan P
Front Neurosci. 2024; 18:1372315.
PMID: 38560047
PMC: 10978728.
DOI: 10.3389/fnins.2024.1372315.
Yadav-Samudrala B, Gorman B, Barmada K, Ravula H, Huguely C, Wallace E
Front Neurosci. 2024; 18:1358555.
PMID: 38505774
PMC: 10949733.
DOI: 10.3389/fnins.2024.1358555.
Xu S, Hao K, Xiong Y, Xu R, Huang H, Wang H
Schizophrenia (Heidelb). 2023; 9(1):77.
PMID: 37935716
PMC: 10630396.
DOI: 10.1038/s41537-023-00406-4.
Ding Y, Wang J, Kumar V, Ciaccio J, Dakhel S, Tan C
Int J Innov Res Med Sci. 2023; 7(6):254-271.
PMID: 37841504
PMC: 10576525.
DOI: 10.23958/ijirms/vol07-i06/1418.
Atypical antipsychotics antagonize GABA receptors in the ventral tegmental area GABA neurons to relieve psychotic behaviors.
Lu C, Zhu X, Feng Y, Ao W, Li J, Gao Z
Mol Psychiatry. 2023; 28(5):2107-2121.
PMID: 36754983
DOI: 10.1038/s41380-023-01982-8.
The effects of preventative cannabidiol in a male mouse model of schizophrenia.
Visini G, Brown S, Weston-Green K, Weickert C, Chesworth R, Karl T
Front Cell Neurosci. 2022; 16:1010478.
PMID: 36406747
PMC: 9669370.
DOI: 10.3389/fncel.2022.1010478.
Cannabidiol but not cannabidiolic acid reduces behavioural sensitisation to methamphetamine in rats, at pharmacologically effective doses.
Umpierrez L, Costa P, Michelutti E, Baracz S, Sauer M, Turner A
Psychopharmacology (Berl). 2022; 239(5):1593-1603.
PMID: 35435462
PMC: 9110442.
DOI: 10.1007/s00213-022-06119-3.
Delta-9-Tetrahydrocannabinol, Cannabidiol, and Acute Psychotomimetic States: A Balancing Act of the Principal Phyto-Cannabinoids on Human Brain and Behavior.
Ganesh S, Cortes-Briones J, Schnakenberg Martin A, Skosnik P, DSouza D, Ranganathan M
Cannabis Cannabinoid Res. 2022; 8(5):846-856.
PMID: 35319274
PMC: 10589482.
DOI: 10.1089/can.2021.0166.
Therapeutic Effects of Cannabidiol on Methamphetamine Abuse: A Review of Preclinical Study.
Razavi Y, Keyhanfar F, Shabani R, Haghparast A, Mehdizadeh M
Iran J Pharm Res. 2022; 20(4):152-164.
PMID: 35194436
PMC: 8842591.
DOI: 10.22037/ijpr.2021.114918.15106.
Cannabidiol and substance use disorder: Dream or reality.
Karimi-Haghighi S, Razavi Y, Iezzi D, Scheyer A, Manzoni O, Haghparast A
Neuropharmacology. 2022; 207:108948.
PMID: 35032495
PMC: 9157244.
DOI: 10.1016/j.neuropharm.2022.108948.
HPA Axis in the Pathomechanism of Depression and Schizophrenia: New Therapeutic Strategies Based on Its Participation.
Mikulska J, Juszczyk G, Gawronska-Grzywacz M, Herbet M
Brain Sci. 2021; 11(10).
PMID: 34679364
PMC: 8533829.
DOI: 10.3390/brainsci11101298.
Cannabidiol Attenuates MK-801-Induced Cognitive Symptoms of Schizophrenia in the Passive Avoidance Test in Mice.
Kruk-Slomka M, Biala G
Molecules. 2021; 26(19).
PMID: 34641522
PMC: 8513030.
DOI: 10.3390/molecules26195977.
HIV Transgenic Rats Demonstrate Impaired Sensorimotor Gating But Are Insensitive to Cannabinoid (Δ9-Tetrahydrocannabinol)-Induced Deficits.
Roberts B, Minassian A, Halberstadt A, He Y, Chatha M, Geyer M
Int J Neuropsychopharmacol. 2021; 24(11):894-906.
PMID: 34338765
PMC: 8598295.
DOI: 10.1093/ijnp/pyab053.
From the Clinic to the Laboratory, and Back Again: Investigations on Cannabinoids and Endocannabinoid System Modulators for Treating Schizophrenia.
Hoffman K
Front Psychiatry. 2021; 12:682611.
PMID: 34290632
PMC: 8287066.
DOI: 10.3389/fpsyt.2021.682611.
Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders.
Navarrete F, Garcia-Gutierrez M, Gasparyan A, Austrich-Olivares A, Manzanares J
Front Pharmacol. 2021; 12:626010.
PMID: 34093179
PMC: 8173061.
DOI: 10.3389/fphar.2021.626010.
Cannabidiol modulation of hippocampal glutamate in early psychosis.
ONeill A, Annibale L, Blest-Hopley G, Wilson R, Giampietro V, Bhattacharyya S
J Psychopharmacol. 2021; 35(7):814-822.
PMID: 33860709
PMC: 8278563.
DOI: 10.1177/02698811211001107.
Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders.
Scarante F, Ribeiro M, Almeida-Santos A, Guimaraes F, Campos A
Front Pharmacol. 2021; 11:618065.
PMID: 33613284
PMC: 7890128.
DOI: 10.3389/fphar.2020.618065.
Medium-Dose Chronic Cannabidiol Treatment Reverses Object Recognition Memory Deficits of Transgenic Female Mice.
Coles M, Watt G, Kreilaus F, Karl T
Front Pharmacol. 2021; 11:587604.
PMID: 33424597
PMC: 7789874.
DOI: 10.3389/fphar.2020.587604.
Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.
Garcia-Gutierrez M, Navarrete F, Gasparyan A, Austrich-Olivares A, Sala F, Manzanares J
Biomolecules. 2020; 10(11).
PMID: 33228239
PMC: 7699613.
DOI: 10.3390/biom10111575.